U-M Hybridoma Core
The U-M Hybridoma Core research laboratory is jointly supported by the University of Michigan Rheumatic Diseases Core Center (RDCC) and the Michigan Diabetes Research and Training Center (MDRTC). It is also affiliated with the Michigan Antibody Technology Center (MATC) in the Michigan Core Technology Alliance, or CTA. U-M Hybridoma Core services are available to all University of Michigan investigators as well as off-campus parties.
The U-M Hybridoma Core generates somatic-cell hybrids (hybridomas) that produce monoclonal antibodies of desired specificity. Since its establishment in 1980, the Hybridoma Core has developed monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, purified proteins, hormones, hormone receptors and recombinant proteins. Our goal is to continue to offer state-of-the-art monoclonal antibody technologies and services to biomedical research investigators.
U-M HC News
The U-M Hybridoma Core will be conducting a pilot study of a potential new service. Soluble proteins secreted by suspension or adherent mammalian cells can be produced in vitro using high density bioreactor flasks (Integra CELLine). In an initial study, milligram amounts of GM-CSF has been successfully produced from a transfected myeloma cell line. The Core is seeking laboratory partners to test the application of this technology with other cell lines. Potential candidates might include but would not be limited to cells transfected with recombinant proteins or other growth factors. Please contact the Core to inquire about participation in the study.
Services
- immunization of mice, rats or hamsters
- fusion of B lymphocytes with myeloma cells to create hybridomas
- expansion and subcloning of hybridomas
- cryopreservation and storage of hybridomas
- monoclonal antibody isotyping
- culture and deposit of hybridomas obtained from other sources
- production of monoclonal antibody by high density culture techniques or in vivo as ascites.
Consultation/Collaboration
Consultation is available from the Hybridoma Core Director on the design of immunization strategies and screening assays to ensure efficient detection of the desired monoclonal antibodies.
The Core also provides collaborative and consultative services in conjunction with the MDRTC Cell & Molecular Biology Core on phage display libraries to assist investigators who may wish to select recombinant antibody-like reagents. Through these initiatives, the Hybridoma Core will remain on the cutting edge of monoclonal antibody technology, and continue to provide optimal service to MDRTC investigators.
